Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
Drug Nomenclature01:17

Drug Nomenclature

1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

111
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
111
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major Adverse Kidney Events in the American Indian or Alaska Native Population with Diabetes.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff.

Drug and alcohol review·2026
Same author

Estimating the daily milligrams of morphine equivalent of illicit fentanyl use in Los Angeles: Clinical and epidemiological implications.

Drug and alcohol dependence·2026
Same author

Dynamic Bayesian networks to predict loss of kidney function: a cross-institution use case in a large cohort with or at-risk of CKD.

BMC medical informatics and decision making·2026
Same author

Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital.

Drug and alcohol review·2026
Same author

Safe inference outside of randomized trials: Application of the stability-controlled quasi-experiment to the effects of three COVID-19 therapies.

Observational studies·2026

Related Experiment Video

Updated: Jun 16, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

527

Enhancing Substance Use Detection in Clinical Notes with Large Language Models.

Fabrice Harel-Canada1, Anabel Salimian2, Brandon Moghanian3

  • 1Computer Science Department, University of California, Los Angeles, 404 Westwood Plaza Suite 277, Los Angeles, 90095, CA, USA.

Research Square
|June 5, 2025
PubMed
Summary
This summary is machine-generated.

Large language models (LLMs) can effectively identify substance use behaviors in electronic health records (EHRs). A fine-tuned LLM achieved high accuracy in detecting various substance use categories, including opioid misuse.

Keywords:
NLPdrug usenatural language processingpeople who inject drugssubstance use

More Related Videos

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

15.9K
Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications
09:20

Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications

Published on: February 23, 2019

8.7K

Related Experiment Videos

Last Updated: Jun 16, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

527
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

15.9K
Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications
09:20

Cloud-Based Phrase Mining and Analysis of User-Defined Phrase-Category Association in Biomedical Publications

Published on: February 23, 2019

8.7K

Area of Science:

  • Medical Informatics
  • Natural Language Processing
  • Public Health Surveillance

Background:

  • Identifying substance use in electronic health records (EHRs) is difficult due to unstructured clinical notes, varied terminology, and negation.
  • Accurate detection is crucial for patient care, clinical decision support, and public health surveillance of substance use behaviors.

Purpose of the Study:

  • To develop and evaluate large language models (LLMs) for detecting eight substance use categories within EHR discharge summaries.
  • To create a large, annotated dataset for drug detection to support systemic substance use surveillance.

Main Methods:

  • Utilized MIMIC-III/IV discharge summaries to construct an annotated drug detection dataset.
  • Investigated the performance of multiple LLMs in zero-shot, few-shot, and fine-tuning settings.
  • Evaluated models on detecting individual substance use, prescription opioid misuse, and polysubstance use.

Main Results:

  • A fine-tuned LLM, Llama-DrugDetector-70B, demonstrated superior performance.
  • Achieved near-perfect F1-scores (>=0.95) for most individual substance use categories.
  • Showed strong performance for prescription opioid misuse (F1=0.815) and polysubstance use (F1=0.917).

Conclusions:

  • LLMs significantly enhance the detection of substance use behaviors in EHRs.
  • Fine-tuned LLMs show promise for clinical decision support and research in substance use surveillance.
  • Further research is needed to address the scalability of LLM applications in this domain.